NUR 7560 Advanced Pharmacology Introduction: Introductions and Foundations of Advanced Pharmacology

Welcome to Week 1 of Advanced Pharmacology

Unit 1 Learning Objectives

• Manage clients who require pharmacotherapeutic interventions by establishing a foundation of facts and an attitude of inquiry to promote effective and safe prescribing CLO 1)
• Integrate resources that can be utilized to monitor pharmacodynamic, pharmacokinetic, and pharmacotherapeutic interaction to maximize client results and to reduce adverse effects or reactions (CLO 2)
• Develop an educational plan that will inform patients about health and drug risks including ethnic and cultural considerations (CLO 1)
• Hypothesize legal and ethical issues in prescribing (CLO 1)
• Prescription writing how to (CLO 1, 4)

• Woo, T. M., & Robinson, M. V. (2020). Pharmacotherapeutics for advanced practice nurse prescribers (5th ed.). F.A. Davis.
  • Chapter 1: The Role of the Advanced Practice Nurse as Prescriber
  • Chapter 2: Review of Basic Principles of Pharmacology
  • Chapter 3: Rational Drug Selection
  • Chapter 4: Legal and Professional Issues in Prescribing
  • Chapter 5: Adverse Drug Reactions

• Woo, T. M., & Robinson, M. V. (2020). Pharmacotherapeutics for advanced practice nurse prescribers (5th ed.). F.A. Davis.
  •  Chapter 1: The Role of the Advanced Practice Nurse Practitioner as Prescriber
  •  Chapter 2: Review of Basic Principles of Pharmacology
  •  Chapter 3: Rational Drug Selection
  •  Chapter 4: Legal and Professional Issues in Prescribing
  •  Chapter 5: Adverse Drug Reactions

• Dunlap, J. (2020). NUR 7560  Chapter 1 – The Role of the Advance Practice Nurse Practitioner as Prescriber.ppsx
• Dunlap, J. (2020). NUR 7560  Chapter 1 – The Role of the Advance Practice Nurse Practitioner as Prescriber-NonRecorded.pptx
• Dunlap, J. (2020). NUR 7560  Chapter 2 – Review of Basic Principles of Pharmacology.ppsx 
• Dunlap, J. (2020). NUR 7560  Chapter 2 – Review of Basic Principles of Pharmacology-Nonrecorded.pptx

• • APA Tutorial ppt Lecture –  APA 7th Edition Tutorial Lecture.ppsx

• •  Prescription Writing for the Nurse Practitioner.ppsx
    • Link 1:
      • Reviews important components of prescriptions and includes examples towards the bottom of the patient. Also of importance is the video titled “How to Write Prescriptions” which is about 1/3 of the way down the page.
      • Medical School Headquarters. (2012, March 23). Prescription writing 101 [Video]. MedicalschoolHQ.net. https://medicalschoolhq.net/prescription-writing-101/
    • Link 2: This is an additional 60 second video found on YouTube that is helpful.
      • Resinger, M. (2017, November 24). How to write a prescription in 60 seconds for PMHNP’s [Video]. YouTube. https://www.youtube.com/watch?v=Zy4ypgvLX8o

• Agency for Healthcare Research and Quality. (n.d.). CHAIN ONLINE: Clinical consumer health advisory information network. U.S. Department of Health and Human Services. https://www.ahrq.gov/chain/index.html
  • Review this page for topics including:
    • Patient Tools
    • Practice Tools

• • Athenahealth, Inc. (n.d). Epocrates. Retrieved March 11, 2021, http://www.epocrates.com/
  • CredibleMeds requires a free registration to access the information. Explore the Medication Safety Tools & Resources section.
  • CredibleMeds. (n.d.). QTDrugs lists. Retrieved March 11, 2021, https://crediblemeds.org/index.php/login/dlcheck
  • Haymarket Media, Inc. (n.d.). Monthly prescribing reference. Retrieved March 11, 2021, http://www.empr.com/ Note: Navigate this site for up-to-date drug safety information and clinical charts that are useful references to print out.

• • Institute for Safe Medication Practices. (2018, August 23). ISMP List of high-alert medications in the acute care settings. https://www.ismp.org/tools/highalertmedications.pdf
  • Institute for Safe Medication Practices. (2011, January 11). ISMP List of high-alert medications in the community/ambulatory healthcare. https://www.ismp.org/communityrx/tools/highAlert-community.pdf
  • Institute for Safe Medication Practices. (2020, February 21). Oral dosage forms that should not be crushed. http://www.ismp.org/tools/donotcrush.pdf

• • U.S. Food and Drug Administration. (n.d.). FDA homepage. U.S. Department of Health and Human Services. https://www.fda.gov/

• International Union of Basic and Clinical Pharmacology. (n.d.). Clinical pharmacodynamics. Pharmacology Education Project. Retrieved November 17, 2021 from https://www.pharmacologyeducation.org/clinical-pharmacology/clinical-pharmacodynamics
  • Click the above link for both a narrative summary as well as short education videos on Clinical pharmacodynamics.
• International Union of Basic and Clinical Pharmacology. (n.d.). Clinical pharmacokinetics. Pharmacology Education Project. Retrieved November 17, 2021 from https://www.pharmacologyeducation.org/clinical-pharmacology/clinical-pharmacokinetics
  • Click the above link for both a narrative summary as well as short education videos on Clinical pharmacokinetics.
• International Union of Basic and Clinical Pharmacology. (n.d.). Adverse drug reactions. Pharmacology Education Project. Retrieved November 17, 2021 from https://www.pharmacologyeducation.org/clinical-pharmacology/adverse-drug-reactions
  • Click the above link for both a narrative summary as well as short education videos on adverse drug reactions.
• International Union of Basic and Clinical Pharmacology. (n.d.). Pharmacology. Pharmacology Education Project. Retrieved November 17, 2021 from https://www.pharmacologyeducation.org/pharmacology
  • Click the above link for both a narrative summary as well as short education videos topics including, but not limited to drug absorption, drug distributions, drug metabolism and drug excretion.

• CLO 1: Apply critical thinking and best scientific evidence to the management and evaluation of expected effects, potential adverse effects, and potential interactions of pharmacological agents for the treatment of self-limiting acute conditions and chronic diseases across the lifespan (MSN PLO 7) (ILO 1,5) (MSN Essential I)
• CLO 4: Evaluate the impact of pharmacogenomics, access, cost, quality, and safety on prescribing. (MSN PLO 5) (ILO 1) (MSN Essential III)

1. In your state, do you need physician collaboration to practice as an NP or can NP’s practice independently? What if any practice restrictions to practice for the NP does your state have?
2. Does the NP role in your state need collaboration to prescribe or can they independently prescribe? What if any prescription restrictions exist in your state (ie: can the NP prescribe all classes of controlled substances in your state, what levels, restrictions such as length of time or quantity limits)?
3. Do you think the NP role should have collaboration for practice? For prescribing? Explain your stance on this position and use scholarly evidenced based information to back it up.
4. Does your state have a Prescription Drug Monitoring Program (PDMP) or Controlled Substance Utilization Review and Evaluation System (CURES) system? If so, what are the details of this system (timeline for uploading of prescriptions to the system, reporting etc.). How will this affect your future FNP practice?

• Include at least 2 scholarly, peer reviewed, timely sources (within 5 years) in your response.
• Writing should be in a professional format with APA appropriate citations and references.
• Please note that on submission to the discussion board, Blackboard often alters the formatting of the post. This is taken into consideration when faculty grade the post.

• Respond to at least 2 peers whose state of practice is different than your own.
• Include at least 1 scholarly, peer reviewed, timely source (within 5 years) in your response.
• Your response should either add to the content of the topic or based on research findings you include ask additional questions on the topic. NUR 7560 Advanced Pharmacology Introduction: Introductions and Foundations of Advanced Pharmacology
• Response should be at least 100 words excluding references.

• Faculty will be present during the week on the discussion board. It is expected that you will respond to any questions posed directly to you by faculty during the week. A failure to respond may result in a deduction of points as indicated in the Discussion Grading Rubric
• Please refer to the grading rubric for further details on the content expectations. You can find this under “My Grades”, “Unit 1: Discussion”.

• CLO 1: Apply critical thinking and best scientific evidence to the management and evaluation of expected effects, potential adverse effects, and potential interactions of pharmacological agents for the treatment of self-limiting acute conditions and chronic diseases across the lifespan (MSN PLO 7) (ILO 1,5) (MSN Essential I)
• CLO 2: Analyze the pharmacodynamics and the pharmacokinetic impact of pharmacologic therapies in the treatment of diseases and altered states. (MSN PLO 1,7) (ILO 1,5) (MSN Essential I)
• CLO3: Formulate therapeutic regimens for patients, including patients with altered pharmacodynamics and pharmacokinetics special populations, such as infants and children, pregnant and lactating women, and older adults with using cultural competence. (MSN PLO 7) (ILO 1) (MSN Essential VIII) NUR 7560 Advanced Pharmacology Introduction: Introductions and Foundations of Advanced Pharmacology
• CLO 4: Evaluate the impact of pharmacogenomics, access, cost, quality, and safety on prescribing. (MSN PLO 5) (ILO 1) (MSN Essential III)
• CLO 5: Examine the significance of interprofessional collaboration on patient outcomes. (MSN PLO 6) (ILO 4) (MSN Essential VIII)

  To complete the following module, you will need to create a free account through the CDC Training and Continueing Education Online page at the following link: https://tceols.cdc.gov/Account/Registration

• Check the functionality of the Respondus Lockdown Browser on your chosen device
• Review course materials including syllabus and course schedule
• Review information from Week 1 including reading materials, Prescription Writing Tutorial, CDC Module
• The Practice quiz is 15 question and is worth 15 points

• CLO 1: Apply critical thinking and best scientific evidence to the management and evaluation of expected effects, potential adverse effects, and potential interactions of pharmacological agents for the treatment of self-limiting acute conditions and chronic diseases across the lifespan (MSN PLO 7) (ILO 1,5) (MSN Essential I) NUR 7560 Advanced Pharmacology Introduction: Introductions and Foundations of Advanced Pharmacology
• CLO 2: Analyze the pharmacodynamics and the pharmacokinetic impact of pharmacologic therapies in the treatment of diseases and altered states. (MSN PLO 1,7) (ILO 1,5) (MSN Essential I)
• CLO3: Formulate therapeutic regimens for patients, including patients with altered pharmacodynamics and pharmacokinetics special populations, such as infants and children, pregnant and lactating women, and older adults with using cultural competence. (MSN PLO 7) (ILO 1) (MSN Essential VIII)
• CLO 4: Evaluate the impact of pharmacogenomics, access, cost, quality, and safety on prescribing. (MSN PLO 5) (ILO 1) (MSN Essential III) NUR 7560 Advanced Pharmacology Introduction: Introductions and Foundations of Advanced Pharmacology